MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B

Launched by SHENGJING HOSPITAL · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to check the severity of liver fibrosis (scarring) in people with chronic hepatitis B, a long-term liver infection. The researchers want to see if a non-invasive test called magnetic resonance elastography (MRE) can accurately assess how severe the fibrosis is. This could help doctors monitor these patients more easily over time without needing more invasive procedures like liver biopsies.

To participate in the study, you need to be at least 18 years old and have a confirmed diagnosis of chronic hepatitis B. You should not have received any treatment for your hepatitis yet, and your liver function should be stable. Participants will undergo MRE scans and possibly a liver biopsy within a 6-month period. The trial is currently looking for volunteers, and anyone who meets the criteria will need to provide their written consent to join. This study could lead to better ways of managing liver health in people with chronic hepatitis B.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• • Confirmed CHB (laboratory, imaging and clinical tests)
• • MRE within 6 months before and after liver biopsy
• • Treatment-naïve
• • Child-Pugh Grade A (\<7 points)
• • Written informed consent in prospective follow-up cohort
• Exclusion Criteria:
• • Patients with liver malignant tumor
• • Chronic hepatitis due to other causes (such as alcoholic hepatitis)
• • CHB combined with hepatitis C, hepatitis D, or HIV
• • Patients with biliary tract diseases
• • Contraindications of MRE examination, MRE failure
• • Poor pathological effect